Gilead Sciences, Inc. vs Eli Lilly and Company
A head-to-head of Gilead Sciences, Inc. (GILD) and Eli Lilly and Company (LLY) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | GILD | LLY |
|---|---|---|
| Market Cap | $160.15B | $823.33B |
| P/E (TTM) | 17.57 | 38.32 |
| Forward P/E | 14.02 | 24.85 |
| P/S | 5.61 | 11.40 |
| P/B | 6.84 | 32.62 |
| EV/EBITDA | 12.15 | 22.78 |
| Dividend Yield | 2.52% | 0.55% |
| Profit Margin | 30.99% | 34.99% |
| Gross Margin | 78.83% | 83.04% |
| Operating Margin | 39.74% | 45.56% |
| Revenue Growth (YoY) | +4.39% | +55.54% |
| FCF Yield | 6.13% | 1.26% |
| Debt / Equity | 94.64 | 139.02 |
| Current Ratio | 1.97 | 1.50 |
Share:
Compare Gilead Sciences, Inc. with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.